Kurt A. Gebauer

Fremantle, WA, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Letter to the Editor Regarding "Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis".

Letter to the Editor Regarding "Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis".

Journal: Dermatology and therapy

Published: February 13, 2026

Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa: A Consensus Exercise Using a Modified Delphi Approach.

Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa: A Consensus Exercise Using a Modified Delphi Approach.

Journal: JAMA dermatology

Published: November 26, 2025

Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study.

Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: November 14, 2025

Retrospective Analysis of the Recurrence of Atypical Fibroxanthoma When Treated With Curettage and Cautery at a Single Centre.

Retrospective Analysis of the Recurrence of Atypical Fibroxanthoma When Treated With Curettage and Cautery at a Single Centre.

Journal: The Australasian journal of dermatology

Published: September 11, 2025

Guidelines for Phototherapy and PUVA Service Delivery in Australia: Minimum Standards and Quality Assurance Framework.

Guidelines for Phototherapy and PUVA Service Delivery in Australia: Minimum Standards and Quality Assurance Framework.

Journal: The Australasian journal of dermatology

Published: May 02, 2025

Consensus on the Use of JAKinibs for Atopic Dermatitis in Australia and New Zealand. An eDelphi by the Australasian Medical Dermatology Group.

Consensus on the Use of JAKinibs for Atopic Dermatitis in Australia and New Zealand. An eDelphi by the Australasian Medical Dermatology Group.

Journal: The Australasian journal of dermatology

Published: March 14, 2025

Delayed Bullous Drug Eruption Induced by Elexacaftor/Tezacaftor/Ivacaftor.

Delayed Bullous Drug Eruption Induced by Elexacaftor/Tezacaftor/Ivacaftor.

Journal: Pediatric dermatology

Published: February 27, 2025

Efficacy and Safety of Switching From Intravenous to Subcutaneous Infliximab for Psoriasis: A Case Series.

Efficacy and Safety of Switching From Intravenous to Subcutaneous Infliximab for Psoriasis: A Case Series.

Journal: The Australasian journal of dermatology

Published: October 08, 2024

Australasian hidradenitis suppurativa management guidelines.

Australasian hidradenitis suppurativa management guidelines.

Journal: The Australasian journal of dermatology

Published: July 11, 2024

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial.

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial.

Journal: Journal of the American Academy of Dermatology

Published: June 24, 2024

From Monotherapy to Adjunctive Therapies: Application of Dermocosmetics in Acne Management Across Australia and New Zealand.

From Monotherapy to Adjunctive Therapies: Application of Dermocosmetics in Acne Management Across Australia and New Zealand.

Journal: The Australasian journal of dermatology

Published: February 06, 2024

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study.

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study.

Journal: Journal of the American Academy of Dermatology

Published: December 01, 2023

Showing 1-12 of 38

Last Updated: 09/26/2026